iBio Study Data Showed Reduced Lean Mass Loss
The company reported that its IBIO-610 antibody improved weight loss composition in a non-human primate study.
Updated on Oct. 13, 2026 in Weight Loss
Live Poll
Should medical treatments for obesity prioritize preserving muscle mass while patients lose weight?
iBio released preclinical study results demonstrating that combining its IBIO-610 antibody with semaglutide targets fat more effectively than semaglutide alone. In an eight-week study, the combination treatment significantly reduced lean mass loss in obese subjects.
Why it matters
The study suggests that IBIO-610 could potentially mitigate a common side effect of current GLP-1 therapies, which often lead to the loss of muscle along with fat. By inhibiting the Activin E ligand, the treatment aims to shift weight loss outcomes toward fat reduction.
The combination treatment resulted in 93% of weight loss coming from fat compared to 77% for semaglutide alone. Additionally, a single dose of IBIO-610 reduced serum levels of the Activin E ligand by 97%.
The players
iBio
This is a biotech company focused on developing pharmaceutical products to address metabolic and chronic diseases.
The details
The non-human primate trial utilized six obese subjects per group, with the combination arm receiving twice-weekly semaglutide alongside a single intravenous dose of the antibody. The antibody targets the ALK7-Smad pathway, which researchers believe blocks natural fat breakdown processes.
Timeline
May 12, 2026: iBio reported fiscal third-quarter 2026 financial results.
October 1, 2026: The study data were presented at the EASD Annual Meeting.
October 13, 2026: iBio released the preclinical study data.
First half of 2027: iBio plans to begin first-in-human studies.
The Big Picture
This study follows a pattern set by the development of GLP-1 receptor agonists, seeking to improve the quality of weight loss outcomes. It reflects a broader industry movement to refine metabolic treatments beyond mere weight reduction.
If successful in human trials, this treatment could provide patients using weight loss drugs a way to preserve lean muscle mass while losing body fat. The projected half-life of the antibody might eventually allow for a twice-yearly dosing schedule.
The takeaway
This preclinical study highlights a potential breakthrough in how weight loss drugs are paired with muscle-preserving treatments. Future human trials will be essential to determine if these metabolic advantages translate to human users.
What happens next
iBio expects to initiate first-in-human clinical trials during the first half of 2027.
Further reading
For more on the evolving landscape of metabolic health, visit Weight Loss.
Live Poll
Should medical treatments for obesity prioritize preserving muscle mass while patients lose weight?
